Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ABVX Abivax S.A.

交易中 08-20 09:31:30 EDT

119.74

-0.82

-0.68%

最高120.02	最低119.65	成交量1.46万
今开120.00	昨收120.56	日振幅0.31%
总市值104.24亿	流通市值91.55亿	总股本8,705万
成交额174.89万	换手率0.02%	流通股本7,646万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ABVX","market":"US","secType":"STK","nameCN":"Abivax S.A.","latestPrice":119.74,"timestamp":1787232681899,"preClose":120.56,"halted":0,"volume":14581,"delay":0,"changeRate":-0.006801592568015987,"floatShares":76455400,"shares":87054500,"eps":-5.216782,"marketStatus":"交易中","change":-0.82,"latestTime":"08-20 09:31:30 EDT","open":120,"high":120.02,"low":119.645,"amount":1748897.33998,"amplitude":0.00311,"askPrice":119.8,"askSize":200,"bidPrice":119.62,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-5.216782,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787256000000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1697774400000,"exchange":"NASDAQ","adjPreClose":120.56,"preHourTrading":{"tag":"盘前","latestPrice":120.01,"preClose":120.56,"latestTime":"09:29 EDT","volume":5389,"amount":651968.845435,"timestamp":1787232599999,"change":-0.55,"changeRate":-0.004562,"amplitude":0.014847},"postHourTrading":{"tag":"盘后","latestPrice":120.56,"preClose":120.56,"latestTime":"19:39 EDT","volume":1073,"amount":129383.09,"timestamp":1787182757501,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":3.810846,"impliedVol":0.6777,"impliedVolPercentile":0.1255},"requestUrl":"/m/hq/s/ABVX","defaultTab":"news","newsList":[{"id":"1100782164","title":"异动解读｜Abivax盘中上涨5.18%，摩根士丹利大幅上调目标价至180美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100782164","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100782164?lang=zh_cn&edition=full","pubTime":"2026-07-30 23:00","pubTimestamp":1785423618,"startTime":"0","endTime":"0","summary":"7月30日，Abivax盘中上涨5.18%，报124.295美元/股，成交额5488.63万美元。消息面上，摩根士丹利近日发布研报，将Abivax目标价从132美元大幅上调至180美元，维持\"增持\"评级。此外，此前市场对标签限制及监管风险的担忧已随临床数据改善而缓解。公司7月初完成约9.2亿美元ADS发行，资金可支撑运营至2029年第四季度，为obefazimod美国商业化提供充足弹药。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114490786","title":"异动解读｜Abivax S.A.盘前上涨6.46%，9.2亿美元增发正式交割提振持续做多情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1114490786","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114490786?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:06","pubTimestamp":1783325216,"startTime":"0","endTime":"0","summary":"7月6日，Abivax S.A.盘前上涨6.46%，报152.5美元/股，成交额58.0万美元。消息面上，公司此前宣布承销商全额行使超额配售权，额外购入96万股ADS，总募资规模从8亿美元扩大至约9.2亿美元，净募集资金约8.74亿美元，该发行于本周一正式完成交割。此前公司公布ABTECT维持试验Part 2积极数据消除安全性争议，叠加发行规模由最初6亿美元两度上调并获超额配售全额认购，机构需求旺盛持续强化市场信心，股价维持在125美元发行价上方运行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165938491","title":"异动解读｜Abivax S.A.夜盘上涨5.74%，9.2亿美元增发正式交割提振持续做多情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1165938491","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165938491?lang=zh_cn&edition=full","pubTime":"2026-07-06 15:01","pubTimestamp":1783321284,"startTime":"0","endTime":"0","summary":"7月6日，Abivax S.A.夜盘上涨5.74%，报152.96美元/股，成交额100.17万美元。消息面上，公司此前宣布承销商全额行使超额配售权，额外购入96万股ADS，总募资规模从8亿美元扩大至约9.2亿美元，净募集资金约8.74亿美元，该发行于本周一正式完成交割。此前公司公布ABTECT维持试验Part 2积极数据，消除安全性争议后股价已大幅反弹，叠加发行规模由最初6亿美元两度上调并获超额配售全额认购，机构需求旺盛持续强化市场信心，股价维持在125美元发行价上方运行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189220198","title":"异动解读｜Abivax S.A.盘中上涨5.39%，承销商全额行使超额配售权总募资扩至9.2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1189220198","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189220198?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:36","pubTimestamp":1782999412,"startTime":"0","endTime":"0","summary":"7月2日，Abivax S.A.盘中上涨5.39%，报140.67美元/股，成交额6686.63万美元。消息面上，公司宣布其ADS公开发行的承销商已全额行使超额配售权，额外购买96万股ADS，总募集金额从8亿美元提升至约9.2亿美元，预计下周一完成交割。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹，当前股价持续高于每股125美元的发行价运行，超额配售全额行使进一步强化市场信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123159008","title":"异动解读｜Abivax S.A.盘前上涨6.27%，8亿美元增发定价完成后市场追捧延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1123159008","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123159008?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:05","pubTimestamp":1782979503,"startTime":"0","endTime":"0","summary":"7月2日，Abivax S.A.盘前上涨6.27%，报140.88美元/股，成交额42.52万美元。消息面上，公司完成8亿美元ADS公开发行定价，以每股125美元发行640万股美国存托凭证，发行规模从此前的6亿美元上调至8亿美元，显示机构认购需求旺盛。募集资金将主要用于核心药物obefazimod在美国的商业化推进及溃疡性结肠炎和克罗恩病的临床研发。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹超38%，本次增发超额扩容进一步确认市场信心，当前股价持续高于发行价运行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140015042","title":"异动解读｜Abivax S.A.夜盘上涨6.37%，8亿美元增发定价完成后市场追捧延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1140015042","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1140015042?lang=zh_cn&edition=full","pubTime":"2026-07-02 15:05","pubTimestamp":1782975924,"startTime":"0","endTime":"0","summary":"7月2日，Abivax S.A.夜盘上涨6.37%，报141.0美元/股，成交额41.41万美元。消息面上，公司完成8亿美元ADS公开发行定价，以每股125美元发行640万股美国存托凭证，发行规模从此前的6亿美元上调至8亿美元，显示机构认购需求旺盛。募集资金将主要用于核心药物obefazimod在美国的商业化推进及溃疡性结肠炎和克罗恩病的临床研发。此前公司公布ABTECT维持试验积极数据消除安全性争议，股价已大幅反弹超38%，本次增发超额扩容进一步确认市场信心，当前股价持续高于发行价运行。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150042476","title":"异动解读｜Abivax S.A.盘中上涨36.68%，三期维持试验补充数据积极消除安全性争议","url":"https://stock-news.laohu8.com/highlight/detail?id=1150042476","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150042476?lang=zh_cn&edition=full","pubTime":"2026-06-30 21:31","pubTimestamp":1782826310,"startTime":"0","endTime":"0","summary":"6月30日，Abivax S.A.盘中上涨36.68%，报131.53美元/股，成交额1.81亿美元。此前50mg组曾因报告多例癌症病例致股价从130美元附近暴跌至约70美元，本次数据消除安全性新增隐患，前期争议逐步消化，多头情绪加速升温。此外，Wedbush将目标价从90美元上调至110美元。公司表示仍计划于第四季度向FDA提交新药上市申请。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178186665","title":"法国生物科技公司Abivax盘前飙升35%，实验性药物最新数据提振市场信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1178186665","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178186665?lang=zh_cn&edition=full","pubTime":"2026-06-30 19:29","pubTimestamp":1782818945,"startTime":"0","endTime":"0","summary":"要点法国生物科技公司 Abivax 公布，其实验性药物 obefazimod 的最新数据显示，恶性肿瘤发生率与预期背景发生率一致，推动公司股价周二盘前大幅上涨。法国生物科技公司 Abivax 周二股价大涨，此前公司公布了其治疗炎症性肠病核心候选药物的最新数据。Abivax 股价盘前上涨35%。Abivax 表示，公司仍计划于2026年第四季度向美国食品药品监督管理局提交 obefazimod 的新药上市申请。","market":"us","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"法国生物科技公司Abivax盘前飙升35%，实验性药物最新数据提振市场信心","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4554","BK4566","BK4543","BK4515","BK4535","BK4581","BK4533","BK4512","BK4020","BK4550","BK4170","BK4585","ABVX","BK4534","BK4579","BK4602","BK4604","BK4532","BK4605","BK4588","BK4553","BK4612","BK4575","BK4141","BK4148","BK4529","BK4527"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1123996127","title":"异动解读｜Abivax S.A.盘前上涨25.85%，三期维持试验补充数据积极驱动股价加速反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1123996127","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123996127?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:00","pubTimestamp":1782806448,"startTime":"0","endTime":"0","summary":"6月30日，Abivax S.A.盘前上涨25.85%，报120.33美元/股，成交额2.18万美元。此前50mg组曾因报告多例癌症病例致股价从130美元附近暴跌至约70美元，跌幅一度近50%。本次补充数据确认疗效并消除安全性新增隐患，前期争议逐步消化，多头情绪加速升温，股价持续回补前期跌幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196891450","title":"异动解读｜Abivax S.A.夜盘上涨27.93%，三期维持试验补充数据积极加速股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1196891450","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196891450?lang=zh_cn&edition=full","pubTime":"2026-06-30 08:05","pubTimestamp":1782777901,"startTime":"0","endTime":"0","summary":"6月30日，Abivax S.A.夜盘上涨27.93%，报123.0美元/股，成交额1230.0美元。消息面上，公司公布ABTECT维持试验Part 2积极数据：50mg obefazimod在诱导期未应答患者中实现37.2%临床缓解率及61.5%临床应答率；维持期复发患者重新用药后应答率和缓解率分别达69.7%和45.0%，且未出现新安全信号。此前50mg组曾报告多例癌症病例致股价一度暴跌近50%，本次补充数据安全性无新增隐患，争议逐步消化叠加疗效确认，多头情绪加速升温，股价持续回补前期跌幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192631370","title":"异动解读｜Abivax S.A.盘后上涨21.37%，三期试验安全性争议持续消化中反弹动能加强","url":"https://stock-news.laohu8.com/highlight/detail?id=1192631370","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192631370?lang=zh_cn&edition=full","pubTime":"2026-06-30 05:07","pubTimestamp":1782767247,"startTime":"0","endTime":"0","summary":"6月30日，Abivax S.A.盘后上涨21.37%，报116.5美元/股，成交额1448.29万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，且该试验已达到主要终点，前期市场反应或过度。近期欧洲医疗保健板块领涨，Abivax在欧洲市场已率先大幅反弹，安全性争议逐步消化背景下多头情绪持续升温，股价加速回补前期跌幅。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138200670","title":"异动解读｜Abivax S.A.盘中上涨5.48%，三期试验安全性争议中多空博弈加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=1138200670","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138200670?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:28","pubTimestamp":1782484132,"startTime":"0","endTime":"0","summary":"6月26日，Abivax S.A.盘中上涨5.48%，报96.91美元/股，成交额5040.65万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元。此后部分投资者认为癌症病例更可能与患者年龄相关，且该试验已达到主要终点，前期反应或过度。近日股价在安全性争议消化过程中持续震荡，多空分歧加剧，当前盘中出现较强反弹。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166922033","title":"异动解读｜Abivax S.A.盘后下跌5.38%，三期试验安全性争议持续压制反弹动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1166922033","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166922033?lang=zh_cn&edition=full","pubTime":"2026-06-26 04:05","pubTimestamp":1782417909,"startTime":"0","endTime":"0","summary":"6月26日，Abivax S.A.盘后下跌5.38%，报92.37美元/股，成交额24.67万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，股价一度反弹至100美元上方。但当前市场对安全性争议的分歧尚未完全消化，技术性反弹动能持续减弱，股价再度回落并延续下行趋势。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148637470","title":"异动解读｜Abivax S.A.盘中下跌5.62%，三期试验安全性争议持续压制反弹动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1148637470","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148637470?lang=zh_cn&edition=full","pubTime":"2026-06-26 00:33","pubTimestamp":1782405206,"startTime":"0","endTime":"0","summary":"6月26日，Abivax S.A.盘中下跌5.62%，报87.205美元/股，成交额9256.07万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，前期反应或过度，股价一度反弹至100美元上方。但当前市场对安全性争议的分歧尚未完全消化，技术性反弹动能持续减弱，股价再度回落并延续下行趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150779863","title":"异动解读｜Abivax S.A.夜盘下跌5.84%，三期试验安全性争议持续压制股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1150779863","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150779863?lang=zh_cn&edition=full","pubTime":"2026-06-25 15:39","pubTimestamp":1782373177,"startTime":"0","endTime":"0","summary":"6月25日，Abivax S.A.夜盘下跌5.84%，报87.11美元/股，成交额33.91万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，前期反应或过度，股价一度反弹至100美元上方。但当前市场对安全性争议的分歧尚未完全消化，技术性反弹动能持续减弱，股价再度回落。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154699591","title":"异动解读｜Abivax S.A.盘中下跌5.15%，三期试验安全性争议未消致反弹行情受阻","url":"https://stock-news.laohu8.com/highlight/detail?id=1154699591","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154699591?lang=zh_cn&edition=full","pubTime":"2026-06-24 22:15","pubTimestamp":1782310523,"startTime":"0","endTime":"0","summary":"6月24日，Abivax S.A.盘中下跌5.15%，报82.65美元/股，成交额7880.38万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后市场部分投资者认为癌症病例更可能与患者年龄相关，前期反应或过度，股价一度反弹至100美元上方。当前股价再度回落，显示市场对安全性争议的分歧尚未完全消化，技术性反弹动能减弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194191893","title":"异动解读｜Abivax S.A.盘中上涨5.15%，三期试验安全性争议消化后股价延续技术性反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1194191893","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194191893?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:59","pubTimestamp":1781708376,"startTime":"0","endTime":"0","summary":"6月17日，Abivax S.A.盘中上涨5.15%，报102.48美元/股，成交额5767.44万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，前期市场反应或过度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160844250","title":"异动解读｜Abivax S.A.盘中上涨5.03%，三期试验安全性争议消化后股价延续技术性反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1160844250","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160844250?lang=zh_cn&edition=full","pubTime":"2026-06-16 00:25","pubTimestamp":1781540736,"startTime":"0","endTime":"0","summary":"6月16日，Abivax S.A.盘中上涨5.03%，报101.41美元/股，成交额7746.5万美元。消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例引发股价自130美元附近暴跌至约70美元，跌幅一度近50%。部分投资者认为癌症病例更可能与患者年龄相关，市场前期反应或过度。当前股价自低位持续回升，反映多空博弈中买方力量阶段性占优。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126571678","title":"异动解读｜Abivax S.A.盘中下跌5.27%，三期试验癌症病例安全性争议叠加证券欺诈调查持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1126571678","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126571678?lang=zh_cn&edition=full","pubTime":"2026-06-10 23:01","pubTimestamp":1781103697,"startTime":"0","endTime":"0","summary":"6月10日，Abivax S.A.盘中下跌5.27%，报97.51美元/股，成交额4363.33万美元。Wedbush Securities指出该药面临黑框警告风险上升。此外，The Schall Law Firm已对公司启动证券欺诈调查，聚焦其是否就临床试验结果发布虚假或误导性陈述。双重利空叠加下，安全性争议及法律风险持续压制市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143782210","title":"异动解读｜Abivax S.A.盘中下跌5.32%，三期试验癌症病例安全性争议持续压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1143782210","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143782210?lang=zh_cn&edition=full","pubTime":"2026-06-08 22:04","pubTimestamp":1780927474,"startTime":"0","endTime":"0","summary":"6月8日，Abivax S.A.盘中下跌5.32%，报97.13美元/股，成交额5404.34万美元。消息面上，公司此前公布核心药物obefazimod治疗中重度活动性溃疡性结肠炎的3期维持试验结果，虽试验达到主要终点且疗效数据位居同类研究前列，但50mg组出现前列腺癌、乳腺癌、结肠异型增生各一例及多例非黑色素瘤皮肤癌，安全性争议仍未消除。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abivax.com","stockEarnings":[{"period":"1week","weight":-0.0395},{"period":"1month","weight":-0.0832},{"period":"3month","weight":-0.028},{"period":"6month","weight":-0.0751},{"period":"1year","weight":0.7483},{"period":"ytd","weight":-0.106}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Abivax Sa是一家于2013年12月4日根据法国法律注册成立。该公司是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法。其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段，并正在开发用于克罗恩病。","exchange":"NASDAQ","name":"Abivax S.A.","nameEN":"Abivax S.A."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Abivax S.A.,ABVX,Abivax S.A.股票,Abivax S.A.股票老虎,Abivax S.A.股票老虎国际,Abivax S.A.行情,Abivax S.A.股票行情,Abivax S.A.股价,Abivax S.A.股市,Abivax S.A.股票价格,Abivax S.A.股票交易,Abivax S.A.股票购买,Abivax S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Abivax S.A.(ABVX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Abivax S.A.(ABVX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}